Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or […]
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V1 Phase 3 Results
Key Takeaways In TRuE-V1, topical ruxolitinib 1.5% cream showed clinically meaningful facial repigmentation versus vehicle by week 24, with continued
Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways For facial vitiligo, pimecrolimus 1% shows superiority over placebo on F-VASI and global assessments in several RCTs/split-face designs.
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities
NB-UVB + Tacrolimus vs NB-UVB Alone in Vitiligo: Randomized Controlled Trial
Key Takeaways Adding topical tacrolimus to NB-UVB is associated with higher facial response rates and earlier perifollicular repigmentation in many
Excimer 308 nm for Focal Vitiligo: Face/Neck Outcomes, Parameters, and Safety
Key Takeaways Excimer 308 nm is well suited for localized/focal lesions, particularly on the face and neck, enabling targeted high-fluence delivery
NB-UVB 311 nm vs PUVA in Vitiligo: Comparative Efficacy and Safety
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
NB-UVB 311 nm for Vitiligo: Cohort Evidence, Protocols, Predictors, and Safety
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens